There are currently 596 clinical trials in Sacramento, California looking for participants to engage in research studies. Trials are conducted at various facilities, including University of California Davis Comprehensive Cancer Center, University of California Davis Medical Center, University Of California Davis and Sutter Medical Center Sacramento. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
The PREDICT Registry:
NCT03448926
Recruiting
This is a prospective, non-interventional (observational) cohort study conducted within the medical network of the participating investigators and institutions. Patients meeting the eligibility criteria (see below) will be eligible for participation and the investigators will obtain written informed consent. A central Institutional Review Board (IRB), WCG IRB, will approve the protocol and each participating institution.
Gender:
FEMALE
Ages:
Between 30 years and 85 years
Trial Updated:
09/03/2024
Locations: Sutter Institute for Medical Research, Sacramento, California
Conditions: DCIS
Register for Updates
The Effects of Topical Almond Oil and Tretinoin on Facial Wrinkles
NCT06571721
Recruiting
Investigate the topical use of almond oil, almond oil augmented with 0.5% vitamin E, 0.025% tretinoin oil augmented with castor oil on the appearance of facial fine lines and wrinkles, pigmentation, hydration, trans-epidermal water loss, and sebum excretion rate.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/26/2024
Locations: Integrative Research Institute, Sacramento, California
Conditions: Collagen Degeneration, Wrinkle, Pigmentation, Elastic Skin, Sebum Deficiency
Register for Updates
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
NCT04372615
Recruiting
Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/26/2024
Locations: UC Davis, Sacramento, California
Conditions: Autoimmune Encephalitis, Encephalitis
Register for Updates
Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea
NCT06072066
Recruiting
The purpose of this study is to evaluate how supplementation will alter the skin and the gut barrier and inflammation in those with rosacea.
Gender:
ALL
Ages:
Between 30 years and 70 years
Trial Updated:
08/26/2024
Locations: Integrative Skin and Research, Sacramento, California
Conditions: Rosacea, Systemic Inflammation
Register for Updates
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
NCT05942248
Recruiting
The study is conducted to determine if image-based computer grading can of acne, melasma, rosacea and seborrheic dermatitis correlate well to expert based clinical severity grading.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/26/2024
Locations: Integrative Skin and Research, Sacramento, California
Conditions: Acne, Melasma, Rosacea, Seborrheic Dermatitis
Register for Updates
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
NCT05548283
Recruiting
The purpose of this study is to look at pulmonary exacerbations in people with cystic fibrosis (CF) that need to be treated with antibiotics given through a tube inserted into a vein (intravenous or IV). A pulmonary exacerbation is a worsening of respiratory symptoms in people with CF that needs medical intervention. Both doctors and CF patients are trying to understand the best way to treat pulmonary exacerbations. This study is trying to answer the following questions about treating a pulmonar... Read More
Gender:
ALL
Ages:
6 years and above
Trial Updated:
08/23/2024
Locations: University of California at Davis Medical Center, Sacramento, California
Conditions: Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
Register for Updates
Fenofibrate for Prevention of DR Worsening
NCT04661358
Recruiting
This randomized trial will evaluate the effect of fenofibrate compared with placebo for prevention of diabetic retinopathy (DR) worsening through 6 years of follow-up in eyes with mild to moderately severe non-proliferative DR (NPDR) and no CI-DME at baseline. In addition to evaluating efficacy, this study aims to evaluate the feasibility of a model for ophthalmologists to prescribe or collaborate with a primary care provider such as an internist/endocrinologist to prescribe and monitor the dru... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/23/2024
Locations: Regents of the University of California, Davis, DBA University of California, Davis, Sacramento, California
Conditions: Diabetic Retinopathy
Register for Updates
Decolonization to Reduce After-Surgery Events of Surgical Site Infection
NCT05586776
Recruiting
The DECREASE SSI Trial (Decolonization to Reduce After-Surgery Events of Surgical Site Infection) is a two-arm multi-center individual placebo-controlled randomized (2,700 participants randomized 1:1) clinical trial to reduce post-discharge surgical site infection following open colon or small bowel surgery by comparing chlorhexidine bathing plus nasal mupirocin in the 30 days following discharge to soap without antiseptic properties (placebo) and placebo nasal ointment. This trial seeks to enha... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/22/2024
Locations: University of California, Davis Medical Center, Sacramento, California
Conditions: Surgical Site Infection
Register for Updates
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
NCT04071457
Recruiting
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Ste... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/21/2024
Locations: Kaiser Permanente Downtown Commons, Sacramento, California +4 locations
Conditions: Multiple Myeloma
Register for Updates
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
NCT06268665
Recruiting
This is a single institution phase II randomized study evaluating the potential benefits of a supplement, tart cherry juice at high- versus low-doses, to prevent taxane induced peripheral neuropathy in breast and ovarian cancer patients undergoing paclitaxel chemotherapy. Eligible participants enrolled onto the study will be block randomized in a 1:1 allocation to either the tart cherry juice high-dose group (Arm 1) or the tart cherry juice low-dose group (Arm 2).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/17/2024
Locations: University of California Davis Comprehensive Cancer Center, Sacramento, California
Conditions: Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage IV, Invasive Breast Cancer, Ovarian Cancer, Ovarian Cancer Stage 1, Ovarian Cancer Stage II, Ovarian Cancer Stage III, Ovarian Cancer Stage IV, Ovarian Cancer Stage IA, Ovarian Cancer Stage IB, Ovarian Cancer Stage IC, Ovarian Cancer Stage 2, Ovarian Cancer Stage 3, Ovarian Cancer Stage IIIb, Ovarian Cancer Stage IIIC, Breast Cancer Stage IIIA, Breast Cancer Invasive, Breast Cancer, Stage IA, Breast Cancer, Stage IB, Breast Cancer Stage IIA, Breast Cancer Stage IIB, Breast Cancer Stage IIIB, Breast Cancer Stage IIIc, Cancer, Breast, Tumors, Breast, Mammary Cancer, Mammary Carcinoma, Breast Carcinoma, Breast Neoplasm, Malignant Breast Neoplasm, Malignant Tumor of Breast, Cancer of Ovary, Ovary Cancer, Ovary Neoplasm
Register for Updates
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
NCT04205968
Recruiting
This phase II trial studies how well ramucirumab and paclitaxel or the FOLFIRI regimen (leucovorin calcium, fluorouracil, and irinotecan hydrochloride) work in treating patients with small bowel cancers that have spread extensively to other anatomic sites (advanced) or are no longer responding to treatment (refractory). Ramucirumab is a monoclonal antibody that attaches to and inhibits a molecule called VEGFR-2. This may restrain new blood vessel formation therefore reducing nutrient supply to t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2024
Locations: Mercy Cancer Center - Sacramento, Sacramento, California
Conditions: Metastatic Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8, Stage IIIA Small Intestinal Adenocarcinoma AJCC v8, Stage IIIB Small Intestinal Adenocarcinoma AJCC v8, Stage IV Small Intestinal Adenocarcinoma AJCC v8
Register for Updates
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
NCT04510597
Recruiting
This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, pembrolizumab, and avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow an... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2024
Locations: Sutter Medical Center Sacramento, Sacramento, California +1 locations
Conditions: Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Register for Updates